Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03680911
Other study ID # 20170856
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date October 12, 2018
Est. completion date January 7, 2020

Study information

Verified date February 2021
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare administration of N-Acetyl Cysteine (NAC) versus placebo for the treatment of olfactory loss due to head injury. The hypothesis is that treatment with NAC acutely after head injury will result in improved olfactory function


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date January 7, 2020
Est. primary completion date January 7, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Admitted to Ryder Trauma Center for observation acutely following head injury (i.e. concussion), with documented hyposmia or anosmia by University of Pennsylvania Smell Identification Test (SIT). - Male or female, aged 18 years or older - Provision of signed and dated informed consent form - Stated willingness to comply with all study procedures and availability for the duration of the study - Ability to take oral medication and be willing to adhere to the NAC regimen - For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of NAC administration Exclusion Criteria: - Severe trauma requiring ongoing inpatient treatment beyond 48 hours - Pregnancy (based on urine screening) or lactation - Known allergic reactions to components of NAC, such as Mucomyst - Currently taking nitrates such as nitroglycerine and/or isosorbide regularly - Currently taking azathioprine (Imuran) or cyclophosphamide (Cytoxan) - Known diagnosis of cystinuria (renal condition in which cysteine supplement should be avoided) - Febrile illness within 1 week - Treatment with another investigational drug or other intervention within 3 months - Active sinonasal disease by imaging and/or nasal exam, i.e. rhinosinusitis, nasal polyps - Adults unable to consent - Prisoners, employees or subordinates - Individuals who are not yet adults (infants, children, teenagers). This population is excluded because efficacy has not yet been established in adults.

Study Design


Intervention

Drug:
N Acetyl Cysteine
2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
Placebo oral capsule
2 g PO BID for 4 days, then 1.5 g PO BID for 2 days

Locations

Country Name City State
United States University Of Miami, Otolaryngology Department Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Olfactory Function Olfactory function will be measured using the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT is a self-administered 40-item test involving microencapsulated (scratch-and-sniff) odors with a forced-choice design. The total score ranges from 0-40 with the higher score indicating better olfactory function. 4 months
Secondary Quality of Life Questionnaire Quality of life will be measured using the questionnaire for Olfactory Disorders (QOD). QOD has a total score from 0-75 with the higher score indicating a better quality of life. 4 months
See also
  Status Clinical Trial Phase
Terminated NCT04964414 - Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19 Phase 1/Phase 2
Completed NCT05445921 - Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction Phase 1/Phase 2
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Withdrawn NCT02179554 - Does Cardiopulmonary Bypass Change Olfaction?
Completed NCT04957563 - Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia N/A
Completed NCT04657809 - Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia Phase 2
Completed NCT04853836 - Olfactory Disfunction and Co-ultraPEALut Phase 4
Recruiting NCT05040659 - Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Recruiting NCT05562050 - Characteristics of the Anosmic Olfactory Mucosa
Completed NCT05152030 - The Clinical Applicability of the 'TIB' Olfactory Test Device
Recruiting NCT05384561 - Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19 N/A
Enrolling by invitation NCT04764981 - Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19) N/A
Withdrawn NCT04408391 - Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
Completed NCT04361474 - Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity Phase 3
Completed NCT03990766 - Smell Changes & Efficacy of Nasal Theophylline Phase 2
Completed NCT04797936 - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 Phase 4
Recruiting NCT04528329 - Anosmia and / or Ageusia and Early Corticosteroid Use Phase 4
Completed NCT04789499 - Smell in Covid-19 and Efficacy of Nasal Theophylline Phase 2
Recruiting NCT04384042 - Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
Completed NCT04390165 - Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study